A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zilovertamab vedotin (Primary)
Indications Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; T-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; First in man
Acronyms waveLINE-001
Sponsors VelosBio

11 Jan 2024 Status changed from active, no longer recruiting to completed.
04 Dec 2023 Planned End Date changed from 30 Oct 2023 to 18 Dec 2023.
04 Dec 2023 Planned primary completion date changed from 1 Sep 2023 to 18 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com